Acetylon Pharmaceuticals Raises $7.25 Million Series A to Develop Next-Generation Selective HDAC Inhibitors

Cambridge-based Acetylon has raised $7.25 million to proceed with preclinical studies for its next generation HDAC6 (histone deacetylase 6) inhibitory drug. While the drug is initially being tested to target multiple myeloma and rheumatoid arthritis, the company believes that its newly selective HDAC inhibitors may find further application to treat neurodegenerative disorders. HDAC6 inhibitors are of particular interest in ALS because there is data to suggest that HDAC6 is involved in regulating various proteins involved in axonal transport including tubulin and possibly dynactin

Click here to read more.

Share this: